Table 3.
Selected clinical trials that incorporate glofitamab in experimental therapy of B-NHL.
| Drug Combination | Target Antigens | Mode of Action of the Combination Agent(s) Other Than Bispecific Antibody | Study Phase | Disease Status | Estimated Study Completion Date | ClinicalTrials.gov Identifier (Other Identifier) |
|---|---|---|---|---|---|---|
| Glofitamab + GemOx compared to rituximab + GemOx | CD20/CD3 | cytostatics gemcitabine and oxaliplatin (GemOx), anti-CD20 rituximab | 3 | R/R DLBCL | March 2022 | NCT04408638 |
| Glofitamab + obintuzumab with obinutuzumab pretreatment | CD20/CD3 | glycoengeneered anti-CD20 obinutuzumab | 1 | R/R B-NHL | June 2022 | NCT03075696 |
| Glofitamab + obintuzumab or rituximab + CHOP with obinutuzumab pretreatment | CD20/CD3 | chemotherapy CHOP, anti-CD20 obintuzumab, anti-CD20 rituximab | 1 | newly dg and R/R B-NHL | December 2023 | NCT03467373 |
| Glofitamab + atezolizumab or polatuzumab-vedotin with obinutuzumab pretreatment | CD20/CD3 | PD-L1 inhibitor atezolizumab, anti-CD79B antibody-drug conjugate polatuzumab-vedotin | 1 | R/R B-NHL | August 2021 | NCT03533283 |
| Glofitamab + RO7227166 with obinutuzumab pretreatment | CD20/CD3 | CD19 Targeted 4-1BB Ligand RO7227166 | 1 | R/R B-NHL | January 2023 | NCT04077723 |
| Glofitamab + lenalidomide +/− obinutuzumab | CD20/CD3 | Immunomodulatory agent lenalidomide | 1 | R/R FL | August 2022 | NCT04246086 |
Abbreviations: CHOP= cyclophosphamide + doxorubicin + vincristine + prednisone; DLBCL= diffuse large B-cell lymphoma; FL= follicular lymphoma; PD-L1= programmed death ligand 1; R/R= relapsed/refractory; B-NHL= B cell non-Hodgkin lymphomas.